Targeted therapy is transforming cancer treatment by focusing on specific genetic mutations and molecular markers rather than using generalized chemotherapy alone.
In Africa, several healthcare and biotechnology companies are strengthening the infrastructure needed to deliver precision oncology, including molecular diagnostics, biomarker testing, and advanced treatment planning.
Here are five Africa-based companies actively contributing to targeted therapy access in 2025:
— Sanger Molecular Diagnostics (Nigeria) provides molecular testing services that help identify actionable mutations in cancer patients, supporting clinicians in selecting targeted treatment options.
— PathCare (South Africa) operates one of Africa’s largest pathology laboratory networks, offering molecular oncology testing that enables personalized and targeted cancer treatment decisions.
— Lancet Laboratories (South Africa, multi-country presence) delivers advanced molecular diagnostics and oncology testing services that inform targeted therapy strategies across Southern and East Africa.
— Revna Biosciences (Ghana) provides molecular diagnostic services and biomedical research support aimed at strengthening precision oncology and targeted treatment planning in West Africa.
— Syndicate Bio (Nigeria) offers genomic and multi-omics testing capabilities that can support oncology research and individualized treatment approaches.
By expanding genomic testing, pathology services, and laboratory capacity, these companies are helping build the clinical foundation required for more precise, evidence-based cancer treatment in Africa.
Methodology: Companies included are Africa-headquartered or Africa-operational entities actively providing molecular diagnostics, genomic testing, or oncology services that support targeted therapy decision-making as of 2025.
Image Credit: Freepik
